This is a routine director sale following an option exercise, with no unusual size or timing. The shares represent a tiny fraction of the company's market cap. Monitor for any Form 4 filing confirming the actual sale, but no material impact is expected.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 4 $930.67entry
- T+1 · 12d ago −2.98%α +1.43% · $902.90
- T+5 · 6d ago +3.09%α +4.00% · $959.41
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Huda Zoghbi filed a Form 144 notice of intent to sell 7,439 shares of Regeneron common stock, with an estimated aggregate market value of approximately $7.22 million based on the filing date. The shares were acquired through a stock option exercise on the same day, and the sale is planned for cash on the open market.
Key Facts
- Filer: Huda Zoghbi, a director of Regeneron Pharmaceuticals
- Shares to be sold: 7,439 shares of common stock
- Estimated aggregate market value: $7,219,262.83
- Shares acquired on 11/03/2026 via stock option exercise from the company
- Broker: UBS Financial Services Inc
- Sale intended for cash on the open market on or after 11/03/2026
- Total shares outstanding per filing: 101,630,713
- Proposed sale represents about 0.0073% of shares outstanding
Financial Impact
Approximately $7.2 million at filing date price, representing about 0.0073% of shares outstanding and an immaterial fraction of the $84.3B market cap
Risk Factors
- Form 144 is an intent to sell; the sale may not be executed
- Director sales, even routine, can be perceived negatively by some market participants
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001969223-26-001124 |
| Document: 0001969223-26-001124-index.html | 0001969223-26-001124 |
| Document: 0001969223-26-001124.txt | 0001969223-26-001124 |
Track record
53 reports on REGN
11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Viewing Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers